An effective dengue vaccine: A glass half full or half empty?

National Medical Journal of India

Volumn 26, Issue 1, 2013, Pages 38-39

  Arya, Vivek ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; PLACEBO; RABIES VACCINE; SODIUM CHLORIDE; VIRUS ANTIGEN;

ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DENGUE; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; MALE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SERODIAGNOSIS; SEROTYPE; THAILAND; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

DENGUE; DENGUE VACCINES; FEMALE; HUMANS; MALE;

EID: 84879296917     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Impact of dengue. Available at http://www.who.int/csr/disease/dengue/impact/en/ (accessed on 12 Dec 2012).
2. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011;29:7229-41
3. Leo YS, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Leong HN, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012;8:1259-71.
4. Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11-year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru. Vaccine 2012;30:5935-41.
5. World Health Organization. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Geneva: WHO; 2008. Available at http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.12_eng.pdf (accessed on 12 Dec 2012).
6. Halstead SB, Heinz FX, Barrett AD, Roehrig JT. Dengue virus: Molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria [conference report]. Vaccine 2005;23:849-56.
7. Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, Thien NT, et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 2007;196:416-24.
8. Pang T, Cardosa MJ, Guzman MG. Of cascades and perfect storms: The immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 2007;85:43-5.
9. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, et al. A phase II, randomized, safety and immunogenicity study of a re-derived, liveattenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 2013;88: 73-8.
10. Anuradha S, Singh NP, Rizvi SN, Agarwal SK, Gur R, Mathur MD. The 1996 outbreak of dengue hemorrhagic fever in Delhi, India. Southeast Asian J Trop Med Public Health 1998;29:503-6.